Inactive

The purpose of Amendment 001 is to attach PDF "52.212-3(MAY2024)_FullText." Response date remains unchanged. ***Please read the attached documents*** The Department of Health and Human Services (HHS),... The purpose of Amendment 001 is to attach PDF "52.212-3(MAY2024)_FullText." Response date remains unchanged. ***Please read the attached documents*** The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Surgery Branch (SB) requires synthesis services for custom biomolecules for the detection of Mutation-Reactive T cells in patients with Metastatic Cancers. This is a Combined Synopsis/Solicitation for commercial items, prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, as supplemented with additional information included in this notice, and shall be processed in accordance with FAR 13.5 - Simplified Procedures for Certain Commercial Products and Commercial Services. This announcement constitutes the only solicitation that will be provided in relation to the stated need contained herein. This solicitation is issued as a Request for Quote (RFQ) and includes applicable provisions and clauses in effect through FAR Federal Acquisition Circular (FAC) 2024-05 (05/22/2024). One firm fixed priced award is anticipated to be made as a result of this solicitation. Please submit questions concerning this RFQ via email no later than 12:00PM EDT on Thursday, 08/08/2024. Quotes in response to this RFQ must be submitted via email no later than 6:00PM EDT on Monday, 08/12/2024.